Introduction:

Inflammatory Bowel Disease Therapeutics Market was valued at US$ 21.8 billion in 2024 and is projected to grow at a CAGR of 3.8% to reach US$ 30.7 billion by 2034.

Inflammatory Bowel Disease (IBD) constitutes a group of chronic inflammatory conditions affecting the gastrointestinal tract, notably the colon and small intestine. Comprising Crohn's disease and ulcerative colitis, IBD manifests through symptoms like abdominal pain, diarrhea, rectal bleeding, weight loss, and fatigue. While its precise etiology remains elusive, IBD is thought to arise from a combination of genetic predisposition, environmental factors, and immune system dysregulation.

Factors such as family history, diet, smoking, and immune responses to intestinal microorganisms contribute to its onset and exacerbation. Although IBD can emerge at any age, it predominantly afflicts individuals between 15 and 30 years old, albeit occurrences in children and older adults are not uncommon. The incidence of IBD is rising globally, particularly in developed countries and urban locales, possibly influenced by changes in lifestyle and environmental exposures. Enhanced understanding of IBD facilitates early detection, appropriate medical interventions, and lifestyle adjustments to mitigate its impact and improve patient outcomes.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Inflammatory Bowel Disease Therapeutics Market Key Drivers:

Crohn's Disease Impact on the IBD Therapeutics Market:

• The growing incidence of Crohn's Disease is driving the demand for treatments in the Inflammatory Bowel Disease (IBD) Therapeutics Market. Pharmaceutical companies are investing in innovative therapies, including biologics and targeted medications, to alleviate symptoms and improve patients' quality of life. This trend is fueling significant growth in the IBD therapeutics sector.      

Expanding Access

• The expansion of treatment options to low-income regions serves as a pivotal market driving factor for the Inflammatory Bowel Disease (IBD) Therapeutics Market. With increased access to affordable treatment alternatives, particularly in economically challenged areas, the market is poised for significant growth.
• Pharmaceutical companies, in collaboration with healthcare organizations and non-profits, are actively working to develop cost-effective therapeutic solutions tailored to the needs of low-income populations. These efforts aim to address the unmet medical needs of individuals with IBD in underserved regions, ultimately expanding the reach and penetration of IBD therapeutics. As treatment options become more accessible and affordable, particularly in low-income areas, the IBD therapeutics market is anticipated to experience notable expansion and diversification in the coming years.

The Impact of OTC Drug Usage on the IBD Therapeutics Market

• The rise in the usage of over-the-counter (OTC) drugs presents a significant market driving factor for the Inflammatory Bowel Disease (IBD) Therapeutics Market. As individuals seek relief from milder symptoms and attempt self-management of their conditions, the demand for OTC medications increases.
• While OTC drugs may provide temporary relief for some IBD symptoms, they often do not address the underlying causes or provide comprehensive management. Consequently, individuals with IBD who rely solely on OTC medications may eventually require prescription therapeutics for effective long-term management.
• This trend underscores the importance of healthcare providers educating patients about the limitations of OTC drugs and the benefits of prescription therapies tailored to their specific needs.
• As awareness grows and individuals increasingly opt for prescription treatments over OTC alternatives, the IBD therapeutics market is expected to witness sustained growth and innovation in response to evolving patient demands.

The Impact of Generic Drug Approvals on the IBD Therapeutics Market:

• The market driving factor of the Inflammatory Bowel Disease (IBD) Therapeutics Market is significantly influenced by the increase in approvals for generic drugs.
• With the approval of generic versions of existing IBD medications, there is heightened competition in the market, leading to lower prices and increased accessibility for patients. Generic drugs offer a more affordable alternative to brand-name medications, making treatment more accessible to a larger patient population.
• As a result, healthcare systems and insurance providers are more inclined to cover the cost of generic IBD drugs, thereby expanding their availability to a broader demographic. Additionally, the introduction of generic options stimulates innovation and research efforts among pharmaceutical companies, driving advancements in IBD therapeutics. Overall, the increase in approvals for generic drugs is a pivotal factor driving growth and accessibility in the IBD therapeutics market.

Inflammatory Bowel Disease Therapeutics Market Restrains:

Cost constrain

• The higher cost of certain treatments serves as a significant restraint in the Inflammatory Bowel Disease (IBD) Therapeutics Market. Expensive medications, especially biologics and targeted therapies, may limit access for patients, strain healthcare budgets, and lead to non-adherence to treatment. Addressing affordability is crucial to ensure equitable access to effective IBD therapies.

Strict Government Regulations

• Strict regulatory guidelines in drug manufacturing pose a restraint in the Inflammatory Bowel Disease (IBD) Therapeutics Market. While crucial for patient safety, these guidelines increase development time and costs, potentially limiting innovation and diversity in treatment options for IBD patients.

Inflammatory Bowel Disease Therapeutics Market is segmented based on Indication, Drug Class, Type of Molecule, Drug Form, Route of Administration and region.

Indication Insight:

• Ulcerative Colitis: Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers in the lining of the colon and rectum. The condition's exact cause remains unclear, although a combination of genetic, environmental, and immune factors is believed to contribute to its development. Symptoms of ulcerative colitis include abdominal pain, diarrhea, rectal bleeding, urgency to have bowel movements, and weight loss, often occurring in periods of flare-ups and remission.

While the disease can affect individuals of any age, it typically emerges in young adults aged 15 to 30, as well as in older adults between 50 and 70. However, it can also manifest in children and older individuals. Management of ulcerative colitis involves medication to reduce inflammation, control symptoms, and prevent complications, along with lifestyle adjustments and, in severe cases, surgical intervention to remove the colon and rectum. The incidence of ulcerative colitis is 9–20 cases per 100,000 people annually.

• Crohn's Disease: Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation and damage to the lining of the digestive system. It can occur anywhere from the mouth to the anus, although it most commonly affects the small intestine and the beginning of the large intestine. The exact cause of Crohn's disease is not fully understood, but it's believed to involve a combination of genetic predisposition, environmental factors, and an abnormal immune response.

While Crohn's disease can develop at any age, it most commonly manifests between the ages of 15 and 35, although it can also occur in children and older adults. Symptoms of Crohn's disease can vary widely but often include abdominal pain, diarrhea, fatigue, weight loss, and malnutrition.

Management typically involves medication to reduce inflammation, alleviate symptoms, and control flare-ups, although in severe cases, surgery may be necessary to remove damaged portions of the digestive tract. Ongoing medical care and lifestyle adjustments are often required to help individuals with Crohn's disease manage their condition effectively and maintain a good quality of life.

Drug Class Insights

• Non-Steroidal Anti-inflammatory drugs (NSAIDs): While NSAIDs are generally not recommended for treating Inflammatory Bowel Disease (IBD) due to their potential to exacerbate symptoms, they still have positive points in other medical conditions. NSAIDs are effective in providing pain relief and reducing inflammation in conditions such as arthritis, musculoskeletal disorders, and acute injuries. They are readily available over the counter and offer rapid relief from pain and discomfort for many individuals.

NSAIDs also play a crucial role in managing mild to moderate pain associated with various acute conditions, allowing patients to maintain their daily activities and quality of life.

• Anti-inflammatory Biologics: Anti-inflammatory biologics, such as infliximab and adalimumab, are crucial in treating Inflammatory Bowel Disease (IBD) like Crohn's disease and ulcerative colitis. These medications target specific parts of the immune system to reduce inflammation in the gut, alleviating symptoms. They are especially beneficial for patients who haven't responded well to traditional therapies or require long-term management.

Biologics offer targeted treatment with fewer systemic side effects compared to conventional options, but they require regular monitoring for potential adverse effects and may increase the risk of infections due to their effects on the immune system. Overall, they have transformed IBD management by providing effective treatment options for patients with moderate to severe conditions.

• Corticosteroids: Corticosteroids are frequently used in the treatment of Inflammatory Bowel Disease (IBD) to help reduce inflammation and alleviate symptoms during flare-ups. Medications like prednisone and budesonide are commonly prescribed to IBD patients experiencing moderate to severe symptoms. Corticosteroids work by suppressing the immune system's inflammatory response in the gut, helping to reduce swelling, pain, and diarrhea associated with IBD. They are particularly effective for short-term management of acute flares and can bring rapid relief to patients.

However, corticosteroids are not typically recommended for long-term use due to their potential for significant side effects, including bone thinning, weight gain, mood changes, and increased susceptibility to infections. Healthcare providers often aim to taper and discontinue corticosteroid therapy as soon as possible, transitioning patients to alternative medications for maintenance therapy. Nonetheless, corticosteroids remain an essential tool in managing IBD flare-ups and improving patients' quality of life when used judiciously and under medical supervision.

Type of Molecule Insights

• Small Molecules: Small molecules like tofacitinib and JAK inhibitors are promising treatments for Inflammatory Bowel Disease (IBD). They target specific pathways in the inflammatory response, reducing gut inflammation and symptoms. Small molecules offer oral administration and are useful for patients not responding to conventional therapies or biologics. Despite risks like infection susceptibility, they represent a hopeful option for those needing alternative treatments in IBD management.
• Biologics: Biologics are crucial in Inflammatory Bowel Disease (IBD) treatment, targeting specific components of the immune system to reduce inflammation in the gut. Medications like infliximab and adalimumab are commonly used examples. They alleviate symptoms and heal the gut lining in patients with moderate to severe IBD, particularly those who haven't responded well to traditional therapies.

While offering targeted therapy with fewer systemic side effects, biologics require regular monitoring for potential adverse effects and may increase infection risk due to immune system effects. Overall, they have transformed IBD management by providing effective treatment options for challenging cases.

Drug Form Insights

• Solid: Solid drug forms, such as tablets and capsules, are essential for Inflammatory Bowel Disease (IBD) treatment. They contain medications like corticosteroids and immunomodulators targeting inflammation and symptoms. These forms offer precise dosing, stable delivery, and convenient administration, promoting treatment adherence. They can be tailored for optimal absorption and efficacy in the gastrointestinal tract. Solid drug forms play a crucial role in long-term IBD management, enhancing treatment outcomes and patient comfort.
• Liquid: Liquid drug forms, such as suspensions and solutions, are important in Inflammatory Bowel Disease (IBD) treatment, especially for patients who have difficulty swallowing solid medications or require precise dosing adjustments. They offer flexibility in dosing, tailored treatment regimens, and ease of administration, particularly for pediatric patients and those with swallowing difficulties. Liquid medications are also beneficial during acute inflammation when oral intake is compromised, as they can be administered via feeding tubes or intravenously for rapid absorption. In summary, liquid drug forms provide convenient and accessible treatment options for patients with diverse needs and circumstances in managing IBD.

Route of Administration Insights

• Parenteral: The parenteral route of administration offers advantages in Inflammatory Bowel Disease (IBD) treatment by bypassing the gastrointestinal tract, ensuring direct and rapid medication absorption. It allows for precise dosing, controlled delivery, and flexibility in administration methods such as intravenous infusion or subcutaneous injection. This route reduces the risk of gastrointestinal side effects associated with oral medications, enhancing treatment tolerability and adherence, especially during acute flare-ups. Overall, parenteral administration provides efficient and reliable delivery of medications in IBD management.
• Oral: The oral route of administration is advantageous in Inflammatory Bowel Disease (IBD) treatment due to its convenience, non-invasiveness, and patient autonomy. Oral medications offer flexibility in dosing, personalized treatment plans, and cost-effectiveness. With a variety of available formulations, they cater to different patient preferences and tolerances. Overall, oral administration remains a key component of IBD management, ensuring effective treatment while promoting patient adherence and comfort.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Inflammatory Bowel Disease Therapeutics Market Regional Insights

• North America: This region is expected to dominate the IBD therapeutics market due to its high disposable income, advanced healthcare infrastructure, and increasing prevalence of IBD cases.
• Asia Pacific: The Asia Pacific region is anticipated to generate the fastest revenue growth in the IBD therapeutics market due to its high population density, rising healthcare expenditures, and increasing awareness about IBD diagnosis and treatment options.
• Europe: Europe benefits from a well-established medical infrastructure and high healthcare expenditures, making it a significant market for IBD therapeutics. The region's advanced healthcare systems and research facilities contribute to the growth of the IBD therapeutics market.
• Latin America: In Latin America, there is an increase in the usage of over-the-counter drugs for managing IBD symptoms due to limited access to healthcare facilities and medications. Despite challenges, the region shows potential for growth in the IBD therapeutics market.
• Middle East & Africa: The Middle East and Africa region is witnessing increasing investments in healthcare infrastructure and initiatives aimed at improving access to healthcare services. This investment is expected to drive the growth of the IBD therapeutics market in the region.

Report Scope:

Attribute	Details
Market Size 2024	US$ 21.8 billion
Projected Market Size 2034	US$ 30.7 billion
CAGR Growth Rate	3.8%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Indication- Ulcerative Colitis and Crohn's Disease By Drug Class- on-Steroidal Anti-inflammatory drugs (NSAIDs), Anti-inflammatory Biologics, and Corticosteroids By Type of Molecule – Small Molecules and Biologics By Drug Form - Solid and Liquid By Route of Administration - Parenteral and Oral
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Inflammatory Bowel Disease Therapeutics Market report based on Indication, Drug Class, Type of Molecule, Drug Form, Route of Administration and region:

Inflammatory Bowel Disease Therapeutics Market, By Indication:

• Ulcerative Colitis
• Crohn's Disease

Inflammatory Bowel Disease Therapeutics Market, By Drug Class:

• Non-Steroidal Anti-inflammatory drugs (NSAIDs)
• Anti-inflammatory Biologics
• Corticosteroids

Inflammatory Bowel Disease Therapeutics Market, By Type of Molecule:

• Small Molecules
• Biologics

Inflammatory Bowel Disease Therapeutics Market, By Drug Form:

• Solid
• Liquid

Inflammatory Bowel Disease Therapeutics Market, By Route of Administration:

• Parenteral
• Oral

Inflammatory Bowel Disease Therapeutics Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Inflammatory Bowel Disease Therapeutics Market includes, Abbvie, Inc., Janssen Biotech Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG., Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Falk Pharma GmbH and Eisai Co, Ltd.

Recent Development:

• In October 2023,  the U.S. Food and Drug Administration (FDA) has approved the once-daily oral medication VELSIPITYTM (etrasimod), a selective sphingosine-1-phosphate (S1P) receptor modulator, for use in patients with moderately to severely active ulcerative colitis (UC). A recommended dose of 2 mg has been approved for VELSIPITY. Those with moderately to highly active UC may be able to achieve steroid-free remission with the aid of VELSIPITY, an oral medicine used once daily that has an excellent benefit-risk profile.
• In October 2023, Teva Pharmaceuticals, an American branch of Teva Pharmaceutical Industries Ltd., and Sanofi have announced a partnership to co-develop and co-commercialize TEV’574, an inflammatory bowel disease treatment currently undergoing Phase 2b clinical trials for Crohn’s disease and ulcerative colitis. Based on the terms of the new cooperation agreement, Teva will receive milestone payments of up to €940 million ($1 billion) for development and launch in addition to an upfront payment of €469 million ($500 million).
• In October 2023, Mirikizumab, a promising induction and maintenance therapy for ulcerative colitis, has received FDA approval, providing patients suffering from this severe and chronic inflammatory bowel disease with a new avenue of treatment. For patients with moderate-to-severely active UC who have not yet shown quick and significant improvements with presently available medications, this therapy provides a safe and efficient therapeutic alternative. Contrary to other UC medications, mirikizumab also relieves bowel urgency, a significant symptom that has a significant negative influence on patients' quality of life.  

• Abbvie, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Janssen Biotech Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis AG.
• Biogen Idec, Inc.
• Cosmo Pharmaceuticals SpA
• ChemoCentryx, Inc.
• Falk Pharma GmbH
• Eisai Co, Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Preface
• Research Objectives
• Study Scope
• Years Considered for the study
• Assumptions
• Abbreviations

Research Methodology

• Research data
• Primary Data
  • Primary Interviews
  • Primary Breakdown
  • Key data from Primary Sources
  • Key Thickness Insights
• Secondary Data
  • Major Secondary Sources
  • Secondary Sources
• Market Estimation
• Top-Down Approach
  • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
• Bottom-Up Approach
  • Approach for estimating market share by Bottom-up Analysis (Demand Side)
• Market Breakdown and Data Triangulation
• Research Assumptions

Market Preview

• Executive Summary
• Key Findings—Global Outlook for medical carts Strategies
  • Key Questions this Study will Answer
  • Market Snippet, By Indication
  • Market Snippet, By Drug Class
  • Market Snippet,  By Type of Molecule
  • Market Snippet, By Drug Form
  • Market Snippet, By Route of Administration
  • Market Snippet, By Region
• Opportunity Map Analysis
• Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Market Opportunities
  • Market Trends
• DR Impact Analysis
• PEST Analysis
• Porter’s Five Forces Analysis
• Opportunity Orbit
• Market Investment Feasibility Index
• Macroeconomic Factor Analysis

Market Segmentation, By Indication, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Ulcerative Colitis
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Crohn's Disease
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Non-Steroidal Anti-inflammatory drugs (NSAIDs)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Anti-inflammatory Biologics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Corticosteroids
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation,  By Type of Molecule, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Small Molecules
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Biologics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Drug Form, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Solid
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Liquid
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Route of Administration, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Parenteral
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Oral
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

• Abbvie, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Janssen Biotech Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• GlaxoSmithKline PLC
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biogen Idec, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
•  Cosmo Pharmaceuticals SpA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• ChemoCentryx, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Falk Pharma GmbH
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eisai Co, Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact